Received Aug 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 324BY | — |
Late Second Dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 68-year-old female patient who received HAB (Twinrix) (batch number 324BY, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix (First they got was about a year ago). On 04-AUG-2025, the patient received the 2nd dose of Twinrix. On 04-AUG-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late Second Dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 04-AUG-2025 Other HCP reported that they had a couple that was leaving to go over the Country this December First So, they were looking to do the expedite schedule. The first they got was about a year ago and the second dose, they got it on the day of reporting. Reporter indicated that by looking at the schedule looked like they had to wait at least two weeks between getting dose number 3, but their question was for dose number four, said it had to be a year after the first dose that had already happened. Asked if there a minimum interval between dose number 3 and 4 they would have to wait, or can they just get dose number four when they come back.; Sender's Comments: US-GSK-US2025100211: